Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00362752 | A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome | PHASE2 | COMPLETED | 9 | — | — | Oct 1, 2006 | Dec 1, 2009 | Dec 7, 2016 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| Norfloxacin 400 mg bid | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Norfloxacin | DRUG | 400 mg po bid |
| Placebo | DRUG | Placebo 400 mg po bid |
Inclusion Criteria: Diagnosis of HPS, based on all of the following: evidence of portal hypertension (esophagogastric varices or portal hypertensive gastropathy identified on esophagogastroduodenoscopy, and/or varices seen on computerized tomography (CT) scan or ultrasound, and/or splenomegaly wit...